Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist

Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist (GA-3)

Lead sponsor

University Hospital, Gentofte, Copenhagen

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Actual enrollment

Study population

Eligibility highlights

•Male

Primary endpoint

•Insulin levels

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03133741

Org study IDUHG-CFD-GIPANTA-3

Timeline

Milestones

Study start2017-03-01actual

Study first posted2017-04-28actual

Primary completion2017-07-01actual

Study completion2017-07-01actual

Last update posted2017-11-01actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexMale

Healthy volunteersAccepted

Inclusion criteria

•Normal kidney function, liver function and hemoglobin levels.

Exclusion criteria

•Medication, Diabetes type 1 or 2, first degree relatives with Diabetes type 2

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

Insulin levels

Time frame:240 minutes

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.